Lasocki, Sigismond http://orcid.org/0000-0003-2901-4628
,
Lefebvre, Thibaud
Mayeur, Claire
Puy, Hervé
Mebazaa, Alexandre
Gayat, Etienne
Funding for this research was provided by:
French ministry of health (PHRC (AON 10-216))
Agence Nationale de la Recherche (ANR-11-IDEX-0005-02)
Article History
Received: 16 August 2018
Accepted: 1 November 2018
First Online: 21 November 2018
Ethics approval and consent to participate
: This study used data obtained from a previously published study, the FROG-ICU study [CitationRef removed,CitationRef removed], conducted in France and Belgium in accordance with Good Clinical Practice (Declaration of Helsinki 2002) and Ethical Committee approvals (Comité de Protection des Personnes—Ile de France IV, IRB n° 00003835 and Commission d’éthique biomédicale hospitalo-facultaire de l’hôpital de Louvain, IRB n°B403201213352).
: Not applicable.
: Sigismond Lasocki has received speaker honoraria from VIFOR Pharma, MASIMO, LFB and fees as a member of the advisory board and/or Steering Committee from VIFOR Pharma and Pfizer. AM received speaker’s honoraria from Abbott, Novartis, Orion, Roche and Servier, and fees as a member of the advisory board and/or Steering Committee from Cardiorentis, Adrenomed, MyCartis, Neurotronik and Sphyngotec. EG received a research grant from Sphingotec, and consultancy fees from Magnisense and Roche Diagnostics. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.